The ARK Genomic Revolution ETF is an actively managed, non-diversified exchange-traded fund that seeks long-term growth of capital. It invests primarily (at least 80% of assets) in domestic and foreign equity securities of companies relevant to the genomics revolution, including businesses focused on gene editing, sequencing, synthetic biology, molecular diagnostics, and AI-enabled drug discovery. The strategy is thematic and actively managed rather than index-linked, and it carries a net expense ratio of 0.75%.
The portfolio typically holds roughly 30 stocks, with healthcare representing essentially the entire equity allocation. The largest positions have recently included Twist Bioscience (TWST), 10x Genomics (TXG), Tempus AI (TEM), CRISPR Therapeutics (CRSP), Personalis (PSNL), Guardant Health (GH), Absci (ABSI), Natera (NTRA), Illumina (ILMN), and CareDx (CDNA). Because a meaningful share of assets sits in small- and mid-cap, pre-profit companies, the fund's concentration and growth tilt amplify both upside momentum and downside volatility. I also checked this using Tickeron’s AI Screener to see how the holdings compare to others in the industry.
Over the trailing 30 days, ARKG advanced from roughly $47.64 to about $53.35, a gain of approximately +12%. The move was not linear: the fund staged a sharp leg higher in the second half of August, consolidated near the low-to-mid $46 range in early September, and then resumed its climb in the back half of September. This pattern is characteristic of a trend-driven but volatile advance rather than a steady, range-bound grind.
The broader three-month picture is stronger still. From a level near $42 at the end of June, ARKG rose to about $53.35, a quarterly gain of roughly +26%. The fund initially pulled back into the mid-$37 area during July before recovering into August, underscoring the high-beta, momentum-sensitive nature of its underlying holdings. From what I see, this volatility is typical for a fund with this kind of exposure.
The recent 30-day rally was propelled by a broad rotation back into high-growth healthcare and biotechnology equities. ARKG's most influential holdings—companies in DNA sequencing, gene editing, liquid biopsy, and AI-accelerated drug development—led the advance, and the fund's concentrated structure allowed a handful of outperformers to drive a disproportionate share of the move.
Several thematic currents supported sentiment. Continued progress in AI-powered biology and drug discovery benefited positions such as Tempus AI and Recursion Pharmaceuticals (RXRX), while sequencing and diagnostics names including Illumina, Natera, and Guardant Health rallied alongside improving demand expectations for genomic testing. Gene-editing developers such as CRISPR Therapeutics, Intellia Therapeutics (NTLA), and Beam Therapeutics (BEAM) also contributed amid renewed optimism around clinical pipelines.
Macroeconomic conditions reinforced the move. A more favorable interest-rate backdrop and firmer investor appetite for long-duration, growth-oriented assets tend to lift the early-stage biotechnology companies that dominate this portfolio. Because many ARKG holdings have earnings concentrated far in the future, their valuations are especially sensitive to changes in discount rates and overall risk sentiment.
The roughly +26% advance over the last quarter reflects a longer-running recovery in the genomics and precision-medicine complex after a mid-year lull. The quarter began with a July pullback in speculative growth names before a sustained rebound took hold, suggesting a genuine rotation into innovation-driven healthcare rather than a short-lived bounce.
Structural drivers underpinned the trend. Sequencing cost declines and expanding clinical adoption of genomic and liquid-biopsy testing continued to broaden the addressable market for diagnostics leaders. Meanwhile, the convergence of machine learning and biology kept AI-native drug-discovery platforms in focus. Institutional ETF flows and improving investor sentiment toward biotechnology also helped sustain the rally, while the fund's non-diversified, small-cap-heavy profile amplified returns during the upswing.
Several factors are likely to shape ARKG over the coming months. Interest-rate expectations and the broader appetite for long-duration growth assets will remain a key swing factor, given the fund's tilt toward pre-profit and early-stage biotechnology companies. Inflation trends and the pace of monetary-policy adjustment will therefore matter as much as company-specific developments.
Investors should monitor the earnings and guidance of the fund's largest diagnostics and sequencing holdings, as well as clinical and regulatory milestones across gene-editing and precision-medicine names. Capital flows into thematic and innovation-oriented ETFs, along with funding conditions for early-stage biotech, could also influence both valuations and sentiment. Finally, the concentrated, non-diversified structure of ARKG means that idiosyncratic moves in a few top positions can meaningfully drive returns in either direction, a risk worth weighing alongside the fund's longer-term genomics investment theme. I'm watching this closely as rate decisions unfold.
In my own analysis, I often rely on Tickeron’s AI Screener to scan for individual stocks and ETFs that align with themes like genomics. It applies technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance data to surface relevant names more efficiently than manual reviews. This has helped me identify breakout candidates and compare holdings within the sector.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
ARKG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 47 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARKG as a result. In 73 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
ARKG moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARKG crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 22 of 22 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARKG entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for ARKG's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 249 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows